Actemra IV

Actemra IV Use In Pregnancy & Lactation





Zuellig Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: There are no adequate data from the use of tocilizumab in pregnant women. A study in monkeys did not indicate any dysmorphogenic potential but has yielded a higher number of spontaneous abortion/embryo-foetal death at a high dose (see Pharmacology: Toxicology: Nonclinical Safety: Other under Actions). The relevance of these data for humans is unknown.
Tocilizumab should not be used during pregnancy unless clearly indicated by medical need.
Nursing Mothers: It is unknown whether tocilizumab is excreted in human breast milk. Although endogenous immunoglobulins of the IgG isotope are secreted into human milk, a systemic absorption of tocilizumab via breast feeding is unlikely due to the rapid proteolytic degradation of such proteins in the digestive system. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with tocilizumab should be made taking into account the benefit of breast-feeding to the child and the benefit of tocilizumab therapy to the woman.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in